Table 1.
Patient’s characteristics
| Characteristics | Hematological disease, non-SCT (n = 244) | ASCT (n = 58) | Allo-SCT (n = 65) | p value |
|---|---|---|---|---|
| Age (years), median (range) | 71 (7–93) | 61 (34–75) | 48 (1–70) | < 0.0001 |
| 0–40 years, n (%) | 20 (8) | 1 (2) | 25 (39) | < 0.0001 |
| 41–60 years, n (%) | 51 (22) | 22 (38) | 21 (32) | |
| 61–70 years, n (%) | 45 (18) | 30 (52) | (17) (26) | |
| >71 years, n (%) | 128 (52) | 5 (8) | 2 (3) | |
| Male, n (%) | 132 (54) | 34 (59) | 40 (61) | 0.5 |
| Baseline disease, n (%) | < 0.0001 | |||
| AML | 44 (19) | 0 | 23 (35) | |
| ALL | 12 (5) | 1 (2) | 12 (18) | |
| MDS | 12 (5) | 0 | 10 (15) | |
| CMPD | 27 (11) | 0 | 2 (3) | |
| NHL | 68 (28) | 17 (30) | 6 (9) | |
| CLL | 2 (10) | 0 | 2 (3) | |
| Plasmatic cell disorder | 40 (16) | 38 (66) | 3 (5) | |
| AA or auto-immune disorders | 13 (6) | 1 (2) | 5 (8) | |
| Disease status, n (%) | < 0.0001 | |||
| CR/PR | 81 (33)/45 (18) | 28 (48)/16 (28) | 56 (86)/0 | |
| Not in remission (Rel/Ref/Prog) | 10 (4)/8 (3)/23 (9) | 5 (8)/1 (2)/6 (10) | 6 (9)/0/2 (3) | |
| Active disease not requiring therapy | 22 (9) | 0 | 0 | |
| Prior lines of therapy | ||||
| 0–1 | 189 (77) | 21 (36) | 26 (40) | < 0.001 |
| > 1 | 55 (23) | 37 (64) | 39 (60) | |
| Allo-SCT, n (%) | ||||
| HLA identical sibling | 29 (45) | |||
| Unrelated Donor | 22 (34) | |||
| Haplo-identical family donor | 14 (21) | |||
| Time from transplant to COVID-19, days (range) | 790 (10–10661) | 441 (6–7597) | 0.1 | |
| Prior therapy/conditioning 40 days before COVID-19, n (%) | 102 (42) | 24 (41) | 10 (15) | < 0.0001 |
| Disease diagnosed within 40 days of COVID-19, n (%) | 60 (25) | 0 | 0 | < 0.0001 |
| Under immunosuppressive drugs before COVID-19 | ||||
| CNI or sirolimus or MMF | 0 | 0 | 28 (43) | < 0.0001 |
| Performance status, n (%) | 0.2 | |||
| ECOG 0–1 | 166 (68) | 48 (82) | 50 (77) | |
| ECOG 2/ECOG 3–4 | 45 (18)/28 (11) | 7 (12)/2 (3) | 7 (11)/5 (8) | |
| Pulmonary/cardiovascular risk factors, n (%) | ||||
| Active smoking | 27 (11) | 4 (7) | 2 (3) | 0.12 |
| Arterial hypertension | 118 (48) | 12 (21) | 12 (18) | < 0.0001 |
| Cardiomyopathy | 51 (21) | 10 (17) | 4 (6) | 0.021 |
| Dyslipidemia | 78 (32) | 11 (19) | 5 (8) | < 0.0001 |
| Diabetes | 9 (4) | 3 (5) | 3 (5) | |
| Median F/U after COVID-19, days (range) | 21 (0–74) | 30 (0–72) | 35 (0–72) | 0.2 |
| Median F/U in survivors, days (range) | 33 (10–74) | 34 (11–72) | 40 (12–72) | 0.2 |
SCT: stem cell transplantation; ASCT: autologous stem cell transplantation; allo-SCT: allogeneic hematopoietic stem cell transplantation; AML: acute myeloid leukemia; ALL: acute lymphoblastic leukemia; MDS: myelodysplastic syndrome; cMPD: chronic myeloproliferative disease; NHL: non-Hodgkin lymphoma; CLL: chronic lymphocytic leukemia; AA: aplastic anemia; CR: complete remission; PR: partial remission; Rel: relapse; Ref: refractory; Prog: progression; CNI: calcineurin inhibitors; MMF: mycophenolate mophetil acid; F/U: follow-up